Advanced

Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of lewy body diseases : Results from a large multicenter cohort

Van Steenoven, Inger; Aarsland, Dag; Weintraub, Daniel; Londos, Elisabet LU ; Blanc, Frederic; Van Der Flier, Wiesje M.; Teunissen, Charlotte E.; Mollenhauer, Brit; Fladby, Tormod and Kramberger, Milica G., et al. (2016) In Journal of Alzheimer's Disease 54(1). p.287-295
Abstract

Background: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers. Objective: We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB). Methods:We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau... (More)

Background: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers. Objective: We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB). Methods:We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal Aβ42 combined with abnormal t-tau and/or p-tau. Results: A substantial proportion of DLB patients had abnormal values for CSF Aβ42, t-tau, and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia.Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF. Conclusion: A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Amyloid beta-protein (1-42), Biomarkers, Cerebrospinal fluid, Dementia with Lewy bodies, Lewy body disease, Tau protein
in
Journal of Alzheimer's Disease
volume
54
issue
1
pages
9 pages
publisher
IOS Press
external identifiers
  • scopus:84984691750
  • wos:000383838400027
ISSN
1387-2877
DOI
10.3233/JAD-160322
language
English
LU publication?
yes
id
cd36c084-6c7e-45dc-b2f8-f7648cb9c97c
date added to LUP
2016-09-21 13:34:11
date last changed
2017-09-24 05:01:00
@article{cd36c084-6c7e-45dc-b2f8-f7648cb9c97c,
  abstract     = {<p>Background: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers. Objective: We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB). Methods:We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal Aβ42 combined with abnormal t-tau and/or p-tau. Results: A substantial proportion of DLB patients had abnormal values for CSF Aβ42, t-tau, and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia.Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF. Conclusion: A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.</p>},
  author       = {Van Steenoven, Inger and Aarsland, Dag and Weintraub, Daniel and Londos, Elisabet and Blanc, Frederic and Van Der Flier, Wiesje M. and Teunissen, Charlotte E. and Mollenhauer, Brit and Fladby, Tormod and Kramberger, Milica G. and Bonanni, Laura and Lemstra, Afina W.},
  issn         = {1387-2877},
  keyword      = {Amyloid beta-protein (1-42),Biomarkers,Cerebrospinal fluid,Dementia with Lewy bodies,Lewy body disease,Tau protein},
  language     = {eng},
  month        = {08},
  number       = {1},
  pages        = {287--295},
  publisher    = {IOS Press},
  series       = {Journal of Alzheimer's Disease},
  title        = {Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of lewy body diseases : Results from a large multicenter cohort},
  url          = {http://dx.doi.org/10.3233/JAD-160322},
  volume       = {54},
  year         = {2016},
}